Displaying 1 - 5 of 5
Author:Howard, James Li, George Vu, Tuan Korobko, Denis Smilowski, Marek Liu, Li Steeland, Sophie Noukens, Jan Van Hoorick, Benjamin Podhorna, Jana Li, Yuebing Utsugisawa, Kimiaki Sacca, Francesco Wiendl, Heinz De Bleecker, Jan Mantegazza, Renato ADAPT-SC Investigator Study Group, in collaboration with the
Session Name:P1: Autoimmune Neurology: Myasthenia Gravis
Topic:Autoimmune Neurology
Program Number:P1.014
Author Institution:The University of North Carolina, Chapel Hill, NC Medsol Clinical Research Center Inc, Port Charlotte, FL University of South Florida, Morsani College of Medicine, Tampa, FL State Budgetary Healthcare Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital", Novosibirsk, Russian Federation Medical University of Silesia, Katowice, Poland argenx, Ghent, Belgium Curare Consulting BV, Etten-Leur, Netherlands Cleveland Clinic, Cleveland, OH Hanamaki General Hospital, Hanamaki, Japan Federico II University of Naples, Napoli, Italy University of Münster, Münster, Germany Ghent University Hospital, Ghent, Belgium Fondazione Istituto Neurologico Carlo Besta, Milan, Italy N/A, Yardley, PA
Author:Sacca, Francesco Costabile, Teresa Signoriello, Elisabetta Lauro, Francesca Altieri, Manuela Ziello, Antonio Rosario d'Ambrosio, Alessandro Bisecco, Alvino Maniscalco, Giorgia Teresa Bonavita, Simona Gallo, Antonio Brescia Morra, Vincenzo Lus, Giacomo Russo, Cinzia Valeria
Session Name:P3: MS Technology, Digital Tools and Artificial Intelligence
Topic:MS and Inflammatory Disease
Program Number:P3.010
Author Institution:University Federico II, Napoli, Italy University of Campania “Luigi Vanvitelli”, Napoli, Italy “A. Cardarelli” Hospital, Napoli, Italy University of Campania “Luigi Vanvitelli”, Naples, Italy
Author:Wiendl, Heinz Cohen, Jeffrey Gold, Ralf De Seze, Jerome Robertson, Derrick Wray, Sibyl Sacca, Francesco Zielman, Ronald Azmon, Amin King, Miriam Fantaccini, Simone Kappos, Ludwig
Session Name:P6: MS Clinical Trials
Topic:MS and Inflammatory Disease
Program Number:P6.016
Author Institution:University of Muenster, Muenster, Germany Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany University Hospital of Strasbourg, Strasbourg, France Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL Hope Neurology MS Center, Knoxville, TN Department (NSRO), University “Federico II” of Naples, Naples, Italy Novartis Pharma B.V., Amsterdam, Netherlands Novartis Pharma AG, Basel, Switzerland Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland
Author:Cohen, Jeffrey Hauser, Stephen Cross, Anne Winthrop, Kevin Wiendl, Heinz Nicholas, Jacqueline Meuth, Sven Giacomini, Paul Sacca, Francesco Zielman, Ronald Das Gupta, Ayan Hu, Xixi Sullivan, Roseanne DeLasHeras, Virginia Kappos, Ludwig
Session Name:P8: MS Therapeutics 2
Topic:MS and Inflammatory Disease
Program Number:P8.004
Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR University of Muenster, Muenster, Germany, Muenster, Germany OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
Author:Sacca, Francesco Carotenuto, Antonio Moccia, Marcello Lanzillo, Roberta Petracca, Maria Brescia Morra, Vincenzo Russo, Cinzia Valeria
Session Name:P13: MS Clinical Assessments and Outcome Measures
Topic:MS and Inflammatory Disease
Program Number:P13.003
Author Institution:University Federico II, Napoli, Italy University Federico II, Naples, Italy University of Rome Sapienza, Rome, Italy Universita Federico II - Napoli, Napoli, Italy University Federico II, Napooli, Italy
Displaying 1 - 5 of 5